Published in J Mol Diagn on July 25, 2016
Analytic Response Curves of Clinical Breast Cancer IHC Tests. J Histochem Cytochem (2017) 0.78
Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis. Sci Rep (2017) 0.75
The Sequence Alignment/Map format and SAMtools. Bioinformatics (2009) 232.39
Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics (2010) 52.01
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics (2014) 44.23
The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem (2009) 40.90
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Mapping copy number variation by population-scale genome sequencing. Nature (2011) 12.55
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Sensitive and accurate detection of copy number variants using read depth of coverage. Genome Res (2009) 7.42
CNVnator: an approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing. Genome Res (2011) 6.97
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist (2009) 6.00
Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics (2011) 5.45
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer (2006) 5.39
CNV-seq, a new method to detect copy number variation using high-throughput sequencing. BMC Bioinformatics (2009) 5.14
Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls. Nat Biotechnol (2014) 4.07
Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol (2012) 3.62
Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res (2003) 3.42
The digital MIQE guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments. Clin Chem (2013) 3.38
HER2 testing in gastric cancer: a practical approach. Mod Pathol (2012) 2.68
Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol (2002) 2.67
CONTRA: copy number analysis for targeted resequencing. Bioinformatics (2012) 2.64
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol (2007) 2.50
cn.MOPS: mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate. Nucleic Acids Res (2012) 2.36
ReadDepth: a parallel R package for detecting copy number alterations from short sequencing reads. PLoS One (2011) 2.34
Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping. Genes Chromosomes Cancer (2000) 2.24
HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw (2006) 2.15
Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov (2013) 2.07
MSB: a mean-shift-based approach for the analysis of structural variation in the genome. Genome Res (2008) 1.79
Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control. Biomed Res Int (2013) 1.61
Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia (2015) 1.44
Molecular cytogenetic analysis of breast cancer cell lines. Br J Cancer (2000) 1.36
Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood (2010) 1.26
ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res (1995) 1.17
Whole-genome CNV analysis: advances in computational approaches. Front Genet (2015) 0.90
Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial. J Mol Diagn (2015) 0.90
Development of genomic DNA reference materials for genetic testing of disorders common in people of ashkenazi jewish descent. J Mol Diagn (2009) 0.89
Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene. Genes Chromosomes Cancer (2002) 0.88
Copy number variation detection using next generation sequencing read counts. BMC Bioinformatics (2014) 0.86
WaveCNV: allele-specific copy number alterations in primary tumors and xenograft models from next-generation sequencing. Bioinformatics (2013) 0.82
Development and characterization of reference materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 genetic testing. J Mol Diagn (2009) 0.81
Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR. J Mol Diagn (2015) 0.81
Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project. J Mol Diagn (2015) 0.81
Development of NIST standard reference material 2373: Genomic DNA standards for HER2 measurements. Biomol Detect Quantif (2016) 0.79
The knowns and the unknowns in HER2 testing in breast cancer. Am J Clin Pathol (2011) 0.76
Plasmid-Based Materials as Multiplex Quality Controls and Calibrators for Clinical Next-Generation Sequencing Assays. J Mol Diagn (2016) 0.78
Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial. J Mol Diagn (2017) 0.75